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Syöpäkasvaimien poikkeava lipidiaineenvaihdunta on todettu sekä in vitro -tutkimuksissa 
syöpäsoluissa että epidemiologisissa tutkimuksissa syöpäpotilaiden poikkeavana 
lipidiprofiilina. Useissa epidemiologisissa töissä matala kokonaiskolesteroli, HDL-kolesteroli ja 
LDL-kolesteroli ovat lisänneet syövän riskiä. Useita aiempia tutkimuksia kuitenkin rajoittaa 
lyhyt seuranta-aika, joidenkin lipidikomponenttien puuttuminen tai kolesterolin 
mittauskertojen vähyys. Tämän tutkimuksen tavoitteena oli tutkia seerumin lipidiprofiilin 
yhteyttä syöpäkuolemaan retrospektiivisessä kohorttitutkimuksessa. Tutkimme myös 
statiinien käytön aikana tapahtuneen kolesterolitason laskun yhteyttä syöpäkuolleisuuteen 
tutkiaksemme mahdollisen syy-yhteyden suuntaa. 
Muodostimme tutkimuskohortin 80,458 Finnish Randomized study of Screening for Prostate 
Cancer (FinRSPC) -tutkimukseen vuosina 1996-1999 osallistuneiden miesten pohjalta. 
Yhdistimme kohortin Fimlabin tietokantaan jolloin löysimme 16,924 miestä, joilta oli mitattu 
kokonaiskolesteroli vähintään kerran. Jaoimme miehet, joilla oli vähintään yksi lipidimittaus 
jonakin vuonna, korkean ja matalan kolesterolin ryhmään käyttäen hyperkolesterolemian 
kliinisiä raja-arvoja. Laskimme riskitiheyssuhteet (hazard ratio, HR) ja 95% luottamusvälit 
(95% CI) Coxin regressiometodia käyttäen sekä syöpäkuolemalle ylipäänsä, että kuolemalle 
eniten syöpäkuolemia aiheuttaviin syöpiin erikseen tarkasteltuna. Pitkän aikavälin yhteyttä 
tutkimme lag time -analyysilla. Käsittelimme seerumin lipidiparametreja aikariippuvaisina 
muuttujina. Suoritimme alaryhmäanalyyseja tutkiaksemme painoindeksin, lääkkeiden 
käytön, oheissairastavuuden sekä kolesterolimittausten lukumäärän vaikutusta lipidiprofiilin 
ja syöpäkuoleman yhteyteen. 
 
 
3 
 
Matala kokonaiskolesteroli oli yhteydessä korkeampaan syöpäkuolleisuuteen. Vastaava 
yhteys todettiin myös matalan HDL-kolesterolin sekä matalan LDL-kolesterolin ja 
syöpäkuoleman riskin välillä. Triglyseridit eivät olleet tilastollisesti merkitsevällä tavalla 
yhteydessä syöpäkuoleman riskiin. Ajallista yhteyttä tutkivissa lag time -analyyseissä tämä 
yhteys oli havaittavissa 10 vuotta ennen syöpäkuolemaa kokonaiskolesterolin osalta, 3 
vuotta ennen syöpäkuolemaa HDL-kolesterolin osalta ja 5 vuotta ennen syöpäkuolemaa LDL-
kolesterolin osalta. Statiinien käytön aikana tapahtunut kolesterolitason lasku oli yhteydessä 
matalampaan syöpäkuoleman riskiin mutta löydös ei ollut tilastollisesti merkitsevä. 
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ABSTRACT 
Background 
Aberrant lipid metabolism has been observed both in vivo in cancer cells as well as in 
epidemiological studies among cancer patients, but many of the studies have major 
limitations and there are discrepancies in the results. 
Materials and methods 
We estimated the long-term associations between serum total cholesterol, LDL, HDL and 
triglycerides and cancer mortality in a retrospective cohort study based on the 80,45 8 men 
identified for the Finnish Randomized study of Screening for Prostate Cancer (FinRSPC) 
during 1996-1999. Total cholesterol measurements were available for 16,924 men. Men with 
lipid measurements available on a given year were stratified into two groups based on 
clinical threshold values. Cox regression method was used to calculate hazard ratios and 95% 
confidence intervals for risk of cancer death overall and separately for death due to most 
commonly fatal cancer types. Serum lipid parameters were analyzed as a time-dependent 
variable. Subgroup analyses were performed to evaluate the effect of BMI, medication use, 
background comorbidities and number of cholesterol measurements on the risk association 
between cholesterol and other lipid parameters and cancer death. Long-term risk 
associations were evaluated in lag time analyses. 
Results 
There was an inverse association between total cholesterol and overall cancer mortality (HR 
0.60, 95% CI 0.46-0.79). Similar inverse risk associations were observed also for HDL (HR 
0.41, 95% CI 0.32-0.53) and LDL cholesterol (HR 0.53, 95% CI 0.39-0.72) but not for 
triglycerides (HR 1.10, 95% CI 0.85-1.42). The inverse association persisted up to 10 years lag 
time for total cholesterol, up to 3 years for HDL, and up to 5 years for LDL cholesterol 
measurements. Compared to those statin users whose serum total cholesterol did not 
decrease or increased during their use of statins, risk of cancer death was decreased for 
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those whose serum total cholesterol decreased by 1.53 mmol/l or less (HR 0.76, CI95% 0.45-
1.29) and for those whose serum total cholesterol decreased by more than 1.53 mmol/l (HR 
0.82, CI95% 0.49-1.39), but the findings were not statistically significant. 
Conclusion 
Low serum total cholesterol is associated with cancer mortality for up to 10 years before 
cancer death, supporting reverse causation. Intervention with statins may lower the risk of 
cancer death, supporting hypercholesterolemia as a modifiable cancer risk factor. 
 
 
 
 
1: INTRODUCTION 
 
Lipids play an important part in cellular membrane structures, energy metabolism and 
signaling1. Aberrant energy metabolism is an established trait of cancer cells2 and this may 
affect also lipid metabolism. Both de novo lipid synthesis3 and exogenous lipid uptake4 have 
been proposed as means for satisfying the high demand posed by fast proliferation. There is 
also evidence that membrane cholesterol is required in the formation of so-called lipid rafts, 
cell membrane microdomains which are mediators of survival signals essential to cancer 
cells5. 
 
Elevated serum total cholesterol is a well-established risk factor for cardiovascular 
disorders1, but its’ role as cancer risk factor is more controversial. The association between 
cancer and serum lipid concentrations has been studied quite extensively6, but many of the 
studies are limited and there are discrepancies in the results. Even though most studies 
report an association between low plasma cholesterol and cancer7–13, there are also studies 
that found no association14,15 or a V-shaped association i.e.  an association between both 
low and high serum cholesterol concentrations and cancer16,17. Some studies focusing on 
colorectal cancer reported a positive association between serum total cholesterol and 
cancer incidence18,19. In many studies the risk association disappeared when the first follow-
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up years were excluded from the analysis, suggesting reverse causation due to 
spontaneously decreasing serum cholesterol due to undiagnosed advanced cancer7–11, but 
there are other studies12,13,20, in which the association between low cholesterol and cancer 
persisted even in the long-term. Reports of an association between use of cholesterol-
lowering statin drugs and lowered cancer mortality compared to non-users further support 
the role of cholesterol in cancer etiology21. 
 
Many of the previous studies are limited by short follow-up or focusing only on total 
cholesterol, without comprehensive data on all lipid components and limited information on 
timing of cholesterol measurements in relation to cancer diagnosis and death. Also many of 
the studies relied on a single cholesterol measurement which makes it harder to determine 
the long-term associations as well as the nature of the possible causal relationship between 
serum cholesterol and cancer. 
 
Because previous evidence on serum total cholesterol as a risk factor for cancer mortality is 
limited, we estimated the long-term associations between total cholesterol, serum LDL, HDL 
and triglycerides and cancer mortality in a population-based cohort of Finnish men. 
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2: MATERIALS AND METHODS 
 
2.1: Study cohort 
 
Our cohort is based on 80,458 men originally identified from the Finnish Population Register 
Centre for the Finnish Randomized study of Screening for Prostate Cancer (FinRSPC) during 
1996-1999. The detailed study protocol has been described earlier22. The men were 55-67 
years old at baseline. Prevalent cases of cancer were identified from the Finnish Cancer 
Registry and excluded. Follow-up started at the FinRSPC baseline in 1996-1999, and 
continued until death, emigration from Finland or 31 December 2015, whichever came first. 
 
Information on causes of death was acquired from the death certificate registry of Statistics 
Finland. The data included immediate, primary and contributory causes of death recorded as 
ICD-10 codes. The registry covers reliably all deaths in Finland by mandatory documentation 
of causes of death. The present study included deaths until the end of 2015. 
Cancer deaths were defined by ICD-10 codes C00-D48 recorded as the primary cause of 
death.  Deaths by cancer type were defined by the following ICD-10 codes: lung cancer C34, 
colorectal cancer C18-C20, pancreatic cancer C25, stomach cancer C22, liver cancer C22, 
non-Hodgkin lymphoma C82, C83 or C85, kidney cancer C64, bladder cancer C67 and brain 
or CNS cancer C71 or C72. 
 
Information on purchases of cholesterol-lowering, antidiabetic and antihypertensive drugs 
as well as on physician-prescribed purchases of aspirin and other non-steroidal anti-
inflammatory drugs (NSAIDs) during 1995-2015 was acquired by linking the cohort to 
national prescription database maintained by the Social Insurance Institution (SII) of Finland. 
The linkage was performed using personal identification number. SII provides 
reimbursements for physician-prescribed drug purchases. All Finnish citizens are entitled to 
the reimbursement. Each reimbursed purchase is registered by the prescription database. 
The registry does not cover drugs used during hospital inpatient periods. 
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To obtain information on co-morbidity diagnoses registered during 1995-2015 the study 
population was linked to the national Care Registry (HILMO) maintained by the National 
Institute for Health and Welfare. HILMO registers all diagnoses from in- and outpatient 
hospital contacts in all Finnish health care units. Diagnoses from the primary care are not 
recorded. Based on recorded diagnoses Charlson Comorbidity Index was calculated for each 
participant to reflect the likelihood of dying of co-morbidities. 
 
A survey with questions about height and weight for calculation of BMI was mailed along 
with the third round FinRSPC screening invitations in 2004-2008. Response rate was 93%, 
and BMI was available for 11,698 men23. 
 
All linkages between data sources were carried out using unique personal identification 
number. 
 
2.2: Information on serum cholesterol parameters 
The study cohort was linked to Fimlab database which registers all laboratory results in the 
Pirkanmaa region. Fimlab is the primary distributor of medical laboratory services in the 
Pirkanmaa region. This way information was acquired on results of serum total cholesterol 
measurements (n=16,924 men with at least one measurement available), LDL (n=15,425), 
HDL (n=15,625) and triglyceride measurements (n=17,043). 
 
Yearly mean of total cholesterol, LDL, HDL and triglycerides was calculated for each follow-
up year using all values measured during a given year. Men with lipid measurements 
available on a given year were stratified into two groups based on clinical threshold values; 
total cholesterol level of 5.0 mmol/l, HDL level of 1.0 mmol/l, LDL level of 3.0 mmol/l and 
triglyceride level of 1.7 mmol/l. Men with no lipid measurements available on a given year 
were categorized into a separate category. 
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2.3: Statistical analysis 
Cox regression method was used to calculate hazard ratios and 95% confidence intervals for 
risk of cancer death overall and separately for death due to most commonly fatal cancer 
types. Deaths due to prostate cancer were included in the overall cancer mortality, but 
prostate cancer-specific death will be analyzed in detail in a separate study. Timeline for the 
follow-up was in years and months since the FinRSPC baseline.  Cox regression was adjusted 
for age and medication use (antidiabetic drugs, antihypertensive drugs, statins, 
anticoagulants, aspirin and other NSAIDs) and additionally for Charlson Comorbidity Index. 
 
Serum lipid parameters were analyzed as time-dependent variable, i.e. the lipid level was 
updated for each follow-up year based on the average of the available yearly measurements. 
 
Subgroup analyses were performed to evaluate the effect of BMI, medication use, 
background comorbidities and number of cholesterol measurements on the risk association 
between cholesterol and other lipid parameters and cancer death. Long-term risk 
associations were evaluated in lag time analyses where serum total cholesterol level was 
lagged forward in the follow-up time, i.e. cholesterol level measured in 2005 was analyzed 
on 2006 in 1-year lag time analysis. We performed separately 1-year, 3-year, 5-year, 10-year 
and 20-year lag time analyses. 
The effect of excess mortality due to non-cancer causes on the risk association was explored 
using competing risks regression method described by Fine and Gray. 
 
All statistical analyses were performed using IBM SPSS 23 statistical software, except the 
competing risks regression analyses which were performed using Stata. 
 
3: RESULTS 
 
3.1: Population characteristics 
The population characteristics are reviewed in table 1. There were 16,924 men in our cohort 
with at least one serum total cholesterol measurement available, 15,625 men with at least 
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one HDL measurement; 15,425 with LDL available and 17,043 men with at least one 
triglyceride measurement. The median number of available total cholesterol measurements 
was seven. When divided into two subgroups by mean total cholesterol during follow-up, 
there were 10,301 men in the group with mean total cholesterol below the clinical 
recommendation of 5 mmol/l or lower and 6,623 in the group with mean total cholesterol 
above 5 mmol/l. 
  
During the median follow-up of 17.2 years after baseline there were 1,430 (8.1% of the 
cohort) cancer deaths among the men with serum total cholesterol measurements available. 
Of these 858 (60.0% of all cancer deaths) occurred in the low total cholesterol group and 
572 (40.0% of all cancer deaths) in the high total cholesterol group. 
 
Age distribution at baseline was similar between the groups. Body mass index was 27.1 in 
the low total cholesterol group and 26.4 in the high total cholesterol group (p for difference 
< 0.001). 
 
Use of statins, antihypertensive drugs, antidiabetic drugs, aspirin and NSAIDs was more 
prevalent in the low total cholesterol group, p for difference by total cholesterol level < 
0.001 for each. The biggest difference was seen in the use of statin drugs; when taking into 
account all available cholesterol measurements, 5,493 (51.5%) men in the low total 
cholesterol group had used statins, while the number of users was 2586 (37.4%) men in the 
high total cholesterol group. When stratifying by baseline cholesterol level, the proportion of 
statin users in the low and high total cholesterol group was 42.8% and 48.4%, respectively 
(Supplementary table 1). 
 
Median Charlson comorbidity index points were 1 for the low total cholesterol group and 0 
for the high total cholesterol group. The median number of cholesterol measurements was 8 
in the low total cholesterol group and 6 in the high total cholesterol group. 
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Table 1. Baseline characteristics of study population by mean cholesterol level during follow-up. 
Cohort of participants in the Finnish Randomized Study of Prostate Cancer Screening between 
1996-2014. 
 
  Mean cholesterol during follow-up  
 Full cohort 5 mmol/l or 
below 
Above 5 mmol/l 
Participants with at least one serum 
total cholesterol measurement available 
(n) 
16,924 10,301 6,623 
Median (IQR) age at baseline (years) 59 (55-63) 59 (55-63) 59 (55-63) 
Number of deaths 5,216 3,136 2,080 
Median (IQR) follow-up time (years) 17.2 (14.2-19.0) 18.0 (16.8-19.0) 18.0 (15.7-19.0) 
Median (IQR) body mass index 
(kg/m2)* 
26.3 (24.3-29.0) 27.1 (24.9-29.9) 26.4 (24.3-29.1) 
Median (IQR) number of 
measurements available 
7 (3-12) 8 (4-13) 6 (3-11) 
Median (IQR) Charlson Co-morbidity 
Index 
1 (0-2) 1 (0-2) 0 (0-2) 
Use of statin drugs; n (%) 8079 (46.0%) 5493 (51.5%) 2586 (37.4%) 
Use of antihypertensive drugs; n (%) 12773 (72.7%) 8325 (78.1%) 4448 (64.4%) 
Use of antidiabetic drugs; n (%) 3957 (22.5%) 2989 (28.0%) 968 (14.0%) 
Use of aspirin; n (%) 3507 (20,0%) 2352 (22.1%) 1155 (16.7%) 
Use of NSAID drugs; n (%) 14196 (80,8%) 8713 (81.7%) 5483 (79.4%) 
Cause of death    
All cancers 1,430 858 572 
Lung cancer 357 207 150 
Colorectal cancer 143 88 55 
Pancreatic cancer 112 70 42 
Gastic cancer 56 33 23 
Liver cancer 71 53 18 
Non-Hodgkin lymphoma 48 32 16 
Kidney cancer 40 25 15 
Bladder cancer 39 24 15 
Brain and CNS cancers 39 24 15 
 
*Available for 11,345 men (67.0% of the cohort)
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Supplement table 1. Baseline characteristics of study population by baseline cholesterol level. 
Cohort of participants in the Finnish Prostate Cancer Screening Trial between 1996-2014. 
 
  Mean cholesterol during follow-up  
 Full cohort 5 mmol/l or 
below 
Above 5 mmol/l 
Participants (n) 16,924 8,134 9,562 
Median (IQR) age at baseline (years) 59 (55-63) 59 (55-63) 59 (55-63) 
Number of deaths 5,216 2,431 2,080 
Median (IQR) follow-up time (years) 17.2 (14.2-19.0) 18.0 (16.3-19.0) 18.0 (16.6-19.0) 
Median (IQR) body mass index 
(kg/m2)* 
26.3 (24.3-29.0) 26.8 (24.7-29.4) 26.8 (24.7-29.6) 
Median (IQR) number of 
measurements available 
7 (3-12) 6 (3-11) 8 (4-13) 
Median (IQR) Charlson Co-morbidity 
Index 
1 (0-2) 1 (0-2) 1 (0-2) 
Use of statin drugs; n (%) 8079 (46.0%) 5493 (42.8%) 2586 (48.4%) 
Use of antihypertensive drugs; n (%) 12773 (72.7%) 8325 (73.7%) 4448 (71.7%) 
Use of antidiabetic drugs; n (%) 3957 (22.5%) 2989 (24.7%) 968 (14.0%) 
Use of aspirin; n (%) 3507 (20,0%) 2352 (19.3%) 1155 (20.3%) 
Use of NSAID drugs; n (%) 14196 (80,8%) 8713 (80.4%) 5483 (80.8%) 
Cause of death    
All cancers 1,432 708 724 
Lung cancer 357 170 187 
Colorectal cancer 143 70 73 
Pancreatic cancer 112 61 51 
Gastic cancer 56 28 28 
Liver cancer 71 42 30 
Non-Hodgkin lymphoma 48 29 19 
Kidney cancer 40 21 19 
Bladder cancer 39 24 15 
Brain and CNS cancers 39 12 27 
 
*Available for 11,345 men (67.0% of the cohort) 
 
 
3.2: Cancer mortality by serum total cholesterol and lipid fractions 
There was an inverse association between total cholesterol and overall cancer mortality (HR 0.60, 
95% CI 0.46-0.79). Similar inverse risk associations were observed also for HDL (HR 0.41, 95% CI 
0.32-0.53) and LDL (HR 0.53, 95% CI 0.39-0.72) cholesterol but not for triglycerides (HR 1.10, 95% 
CI 0.85-1.42) (Table 2). 
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In lag time analyses the inverse association remained up to 10 years lag time for total cholesterol, 
3 years for HDL, and 5 years for LDL cholesterol measurements. In longer-term lag time analyses 
the risk estimates tended to rise for total cholesterol, up to HR 1.68 (95% CI 0.75-3.80) in the 20-
year lag time analysis. A similar trend of rising risk estimates was seen also for HDL cholesterol. For 
LDL cholesterol and triglycerides, a similar rise in risk estimates was observed, albeit not as 
consistent. Interestingly, even though the main analysis did not show a significant association 
between triglyceride levels and cancer mortality, marginally non-significant positive associations 
between high triglyceride levels and cancer mortality were observed in the long-term analyses. 
 
Similar inverse association disappearing with time were also observed when analyzing individual 
cancer types for total cholesterol, HDL and LDL in relation to cancer mortality. There was no 
substantial variation in the association patterns depending on the cancer type. 
 
Lung cancer death displayed an inverse association with total cholesterol that persisted up to five 
years in the lag time analysis and an inverse association with LDL cholesterol up to 3 years in the  
lag time analysis (table 3). There was no statistically significant association between lung cancer 
death and HDL cholesterol or triglycerides. 
 
Colorectal cancer death was not significantly associated with total cholesterol or LDL (table 3). 
There was an inverse association between HDL cholesterol and colorectal cancer death persisting 
up to 1 year in the lag time analysis. High triglyceride levels were statistically significantly 
associated with colorectal cancer death, but the finding disappeared in 1-year lag time analysis. 
  
Pancreatic cancer showed an inverse association with HDL cholesterol (table 3). The association 
persisted up to 3 years in the lag time analysis. Other lipid fractions did not display statistically 
significant associations with pancreatic cancer death. 
 
Of the less common cancer types (supplement table 2) risk of liver cancer death displayed an 
inverse association with cholesterol, LDL cholesterol and HDL cholesterol but no statistically 
significant association with triglycerides. The association with total cholesterol and LDL cholesterol 
for liver cancer death was only observed in the lag time analyses; the association with total 
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cholesterol persisted up to 3 years and the association with LDL cholesterol up to 1 year. The 
association with HDL persisted up to 1 year. 
 
Non-Hodgkin lymphoma and bladder cancer showed inverse associations with HDL cholesterol 
levels that disappeared in the 3-year lag time analysis for non-Hodgkin lymphoma and 1-year lag-
time analysis for bladder cancer. In kidney cancer, a consistently rising positive association was 
observed with triglyceride levels, but it was statistically significant only in the 10-year lag time 
analysis. Mortality from stomach cancer and cancers of the brain and central nervous system were 
not associated with any of the lipid fractions with statistical significance. 
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Table 2.  Serum total cholesterol and lipid fraction levels and risk of all-cancer death. 
 
 
   Lag time   
  Main analysis 1yr 3yrs 5 yrs 10yr 20yr 
 N of 
deaths 
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
Serum cholesterol 
(mmol/l) 
      
5 or lower 858 Ref Ref Ref Ref Ref Ref 
above 5 572 0.60 
(0.46-0.79) 
0.68 
(0.57-0.82) 
0.75 
(0.63-0.89) 
0.73 
(0.61-0.88) 
0.74 
(0.56-0.96) 
1.68 
(0.75-3.80) 
      
LDL cholesterol (mmol/l)       
3 or lower 785 Ref Ref Ref Ref N/A N/A 
above 3 314 0.53 
(0.39-0.72) 
0.64 
(0.52-0.79) 
0.76 
(0.63-0.93) 
0.70 
(0.55-0.88) 
  
Triglycerides        
1.7 or lower 1067 Ref Ref Ref Ref Ref Ref 
above 1.7 391 1.10 
(0.85-1.42) 
1.19 
(0.99-1.44) 
1.19 
(0.99-1.42) 
1.17 
(0.96-1.42) 
1.22 
(0.92-1.61) 
1.35 
(0.75-2.42) 
HDL cholesterol      
1.0 or lower 271 Ref Ref Ref Ref N/A N/A 
above 1.0 869 0.41 
(0.32-0.53) 
0.64 
(0.53-0.78) 
0.69 
(0.56-0.85) 
0.88 
(0.69-1.14) 
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Table 3. Serum total cholesterol and lipid fraction levels and risk of cancer death by the most common cancer types. 
 
   Lag time    
  Main analysis 1yr 3yr 5yr 10yr 20yr 
 N of deaths 
(non-exposed/exposed*) 
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
Lung cancer deaths:       
Total 
cholesterol 
207/150 0.64 
(0.38-1.09) 
0.63 
(0.44-0.91) 
0.64 
(0.37-0.78) 
0.59 
(0.40-0.87) 
0.63 
(0.36-1.13) 
0.81 
(0.16-4.19) 
 
LDL 192/79 0.52 
(0.28-0.98) 
0.52 
(0.34-0.79) 
0.52 
(0.34-0.80) 
0.75 
(0.47-1.20) 
N/A N/A  
HDL 53/225 0.85 
(0.46-1.57) 
0.72 
(0.48-1.07) 
0.92 
(0.59-1.45) 
1.20 
(0.67-2.17) 
N/A N/A  
Triglycerides 267/91 0.82 
(0.46-1.46) 
1.06 
(0.72-1.54) 
1.23 
(0.86-1.79) 
0.88 
(0.57-1.36) 
1.43 
(0.80-2.58) 
2.37 
(0.59-9.49) 
 
Colorectal cancer deaths:        
Total 
cholesterol 
88/55 0.74 
(0.29-1.89) 
0.72 
(0.38-1.35) 
0.57 
(0.32-1.00) 
0.68 
(0.39-1.18) 
0.99 
(0.45-2.22) 
1.47 
(0.16-13.13) 
 
LDL 85/26 0.82 
(0.29-2.30) 
0.61 
(0.30-1.24) 
0.62 
(0.33-1.17) 
0.73 
(0.36-1.45) 
N/A N/A  
HDL 30/84 0.29 
(0.11-0.73) 
0.50 
(0.26-0.96) 
0.84 
(0.44-1.63) 
0.76 
(0.36-1.59) 
N/A N/A  
Triglycerides 111/37 2.18 
(1.01-4.74) 
1.54 
(0.83-2.86) 
0.94 
(0.51-1.72) 
0.77 
(0.40-1.48) 
0.35 
(0.10-1.17) 
0.78 
(0.13-4.68) 
 
Pancreatic cancer deaths:       
Total 
cholesterol 
70/42 0.83 
(0.35-1.99) 
0.60 
(0.33-1.12) 
0.71 
(0.39-1.30) 
0.75 
(0.38-1.45) 
2.25 
(0.88-5.75) 
1.06 
(0.11-10.17) 
 
LDL 62/24 0.95 
(0.36-2.47) 
0.99 
(0.54-1.82) 
0.55 
(0.27-1.16) 
1.00 
(0.45-2.20) 
N/A N/A  
HDL 20/68 0.29 
(0.12-0.69) 
0.44 
(0.24-0.81) 
0.45 
(0.24-0.85) 
1.33 
(0.46-3.81) 
N/A N/A  
Triglycerides 87/28 0.85 
(0.32-2.25) 
0.81 
(0.41-1.61) 
1.00 
(0.52-1.90) 
1.13 
(0.56-2.27) 
1.54 
(0.68-3.46) 
1.09 
(0.15-7.74) 
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* Low cholesterol values/high cholesterol values
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Supplement table 2. Serum total cholesterol and lipid fraction levels and risk of cancer death by less common cancer types 
 
   Lag time    
  Main analysis 1yr 3yr 5yr 10yr 20yr 
 N of deaths 
(non-exposed/exposed*) 
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
Stomach cancer deaths:       
Total 
cholesterol 
33/23 0.63 
(0.20-1.94) 
1.98 
(0.87-4.50) 
1.12 
(0.50-2.53) 
0.60 
(0.21-1.69) 
1.03 
(0.23-4.60) 
N/A  
LDL 25/11 0.59 
(0.16-2.16) 
0.81 
(0.29-2.31) 
0.95 
(0.36-2.52) 
0.32 
(0.07-1.43) 
N/A N/A  
HDL 7/29 0.70 
(0.19-2.54) 
0.92 
(0.26-3.21) 
0.95 
(0.28-3.29) 
2.46 
(0.32-18.84) 
N/A N/A  
Triglycerides 47/12 0.57 
(0.13-2.49) 
0.88 
(0.30-2.61) 
0.16 
(0.02-1.16) 
0.45 
(0.10-1.98) 
0.60 
(0.07-5.38) 
2.57 
(0.23-28.40) 
 
Liver cancer deaths:        
Total 
cholesterol 
53/18 0.76 
(0.25-2.37) 
0.39 
(0.16-0.92) 
0.32 
(0.12-0.83) 
0.47 
(0.21-1.04) 
1.00 
(0.34-2.97) 
0.17 
(0.02-1.88) 
 
LDL 40/10 0.27 
(0.03-2.15) 
0.33 
(0.12-0.93) 
0.56 
(0.21-1.50) 
0.32 
(0.10-1.07) 
N/A N/A  
HDL 20/34 0.09 
(0.02-0.32) 
0.47 
(0.24-0.95) 
0.61 
(0.25-1.46) 
0.60 
(0.25-1.45) 
N/A N/A  
Triglycerides 44/29 1.79 
(0.66-4.84) 
1.11 
(0.54-2.28) 
1.14 
(0.53-2.47) 
1.60 
(0.81-3.20) 
0.60 
(0.17-2.19) 
0.53 
(0.05-5.85) 
 
Non-Hodgkin lymphoma deaths:       
Total 
cholesterol 
32/16 0.46 
(0.10-2.09) 
0.34 
(0.10-1.17) 
0.20 
(0.05-0.85) 
0.22 
(0.05-0.99) 
0.18 
(0.02-1.54) 
N/A  
LDL 33/5 N/A 0.12 
(0.02-0.87) 
0.29 
(0.07-1.25) 
N/A N/A N/A  
HDL 14/27 0.07 
(0.01-0.32) 
0.29 
(0.12-0.68) 
0.59 
(0.21-1.65) 
0.58 
(0.18-1.82) 
N/A N/A  
Triglycerides 34/13 1.63 
(0.51-5.21) 
0.64 
(0.19-2.18) 
0.19 
(0.03-1.44) 
2.41 
(0.92-6.36) 
0.51 
(0.06-4.34) 
0.60 
(0.06-6.65) 
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Kidney cancer deaths:       
Total 
cholesterol 
25/15 0.72 
(0.15-3.57) 
0.63 
(0.17-2.31) 
0.37 
(0.11-1.27) 
0.72 
(0.19-2.80) 
1.67 
(0.42-6.67) 
N/A 
 
 
LDL 22/11 0.88 
(0.17-4.55) 
0.73 
(0.20-2.70) 
0.56 
(0.16-2.02) 
0.85 
(0.17-4.41) 
N/A N/A  
HDL 9/25 0.59 
(0.11-3.05) 
1.08 
(0.24-4.95) 
0.37 
(0.12-1.10) 
1.21 
(0.15-10.03) 
N/A N/A  
Triglycerides 31/11 0.56 
(0.07-4.55) 
1.32 
(0.36-4.89) 
1.62 
(0.57-4.61) 
3.43 
(0.99-11.88) 
4.85 
(1.21-19.41) 
N/A  
Bladder cancer deaths:       
Total 
cholesterol 
24/15 1.15 
(0.29-4.62) 
0.56 
(0.19-1.67) 
0.52 
(0.14-1.89) 
1.24 
(0.39-3.92) 
2.61 
(0.53-12.97) 
N/A  
LDL 22/12 0.64 
(0.13-3.08) 
0.73 
(0.24-2.28) 
2.09 
(0.67-6.51) 
0.92 
(0.24-3.57) 
N/A N/A  
HDL 4/30 0.19 
(0.05-0.72) 
0.71 
(0.23-2.18) 
2.51 
(0.33-19.32) 
N/A N/A N/A  
Triglycerides 30/8 1.15 
(0.24-5.37) 
1.46 
(0.53-4.06) 
1.06 
(0.30-3.81) 
1.15 
(0.31-4.25) 
1.51 
(0.36-6.35) 
N/A  
Brain and CNS cancer deaths:       
Total 
cholesterol 
24/15 0.33 
(0.07-1.47) 
0.46 
(0.17-1.23) 
1.79 
(0.69-4.65) 
1.85 
(0.69-4.99) 
1.52 
(0.14-16.77) 
N/A  
LDL 20/11 0.38 
(0.08-1.74) 
0.46 
(0.15-1.37) 
2.38 
(0.88-6.42) 
1.59 
(0.53-4.74) 
N/A N/A  
HDL 3/30 0.62 
(0.17-2.31) 
1.97 
(0.46-8.46) 
3.02 
(0.40-22.82) 
1.06 
(0.23-4.78) 
N/A N/A  
Triglycerides 33/6 0.72 
(0.16-3.27) 
0.81 
(0.28-2.38) 
0.83 
(0.24-2.90) 
1.15 
(0.37-3.59) 
4.94 
(0.45-54.58) 
N/A  
 
* Low cholesterol values/high cholesterol values 
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3.3: Cancer mortality by changes in cholesterol level after initiation of statin use 
Compared to those statin users whose serum total cholesterol did not decrease or increased after the first statin purchase, risk of cancer death 
was non-significantly decreased among those whose serum total cholesterol decreased by 1.53 mmol/l or less (HR 0.76, CI95% 0.45-1.29) and 
for those whose serum total cholesterol decreased by more than 1.53 mmol/l (HR 0.82, CI95% 0.49-1.39) (table 4). Similar associations were 
not observed for decreases in LDL cholesterol or triglycerides during statin use. 
 
Table 4. Change in serum cholesterol after initiation of statin treatment and cancer mortality. 
 
 Change in 
 Total cholesterol LDL Triglycerides 
 None or 
increased 
Decrease by 1.52 
mmol/l or less 
Decreased 
more than 
1.52 
mmol/l 
None or 
increased 
Decrease 
by 0.96 
mmol/l or 
less 
Decreased more 
than 0.96 mmol/l 
None or 
increased 
Decrease by 
0.30 mmol/l or 
less 
Decreased more than 
0.30 mmol/l 
Risk of cancer death         
          
HR (95% 
CI) 
Ref 0.76 
(0.45-1.29) 
0.82 
(0.49-
1.39) 
Ref 0.95 
(0.43-
2.09) 
1.55 
(0.75-3.21) 
Ref 0.96 
(0.69-1.33) 
1.00 
(0.76-1.33) 
N of 
cancer 
deaths 
155 130 17 51 23 9 157 78 75 
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3.4: Subgroup analyses 
There was no clear effect modification by BMI, statin use or number of available cholesterol measurements (table 4). 
 
Subgroup analysis by Charlson comorbidity index (table 4) showed no effect modification for total cholesterol, LDL or triglyceride levels. An 
exception was HDL cholesterol; those with no co-morbidities displayed an inverse association between HDL levels and cancer mortality (HR 
0.14, CI95% 0.05-0.37) while among men with most co-morbidities (Charlson Index 3 points or more) displayed a weaker risk association (HR 
0.67, CI95% 0.46-0.96), p for interaction = 0.001.
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Table 4: subgroup analysis by BMI, statin use, number of serum total cholesterol measurements and Charlson comorbidity index. 
 
 Subgroup analysis by BMI Subgroup analysis by statin use  
  BMI 26.3 or 
lower 
BMI over 26.3  No statin use Statin use  
 N of deaths 
(low BMI/high 
BMI) 
HR (95% CI) HR (95% CI) N of deaths 
(no statin use/ 
statin use) 
HR (95% CI) HR (95% CI)  
Serum cholesterol (mmol/l)       
5 or lower 49/57 Ref Ref 482/376 Ref Ref  
above 5 31/36 0.34 
(0.04-2.62) 
1.04 
(0.44-2.47) 
347/225 0.57 
(0.41-0.81) 
0.64 
(0.41-1.00) 
 
LDL cholesterol (mmol/l)       
3 or lower 48/60 Ref Ref 381/404 Ref Ref  
above 3 22/25 0.38 
(0.05-3.03) 
0.33 
(0.10-1.10) 
198/116 0.49 
(0.33-0.72) 
0.52 
(0.31-0.90) 
 
Triglycerides (mmol/l)       
1.7 or lower 70/63 Ref Ref 667/400 Ref Ref  
above 1.7 10/30 4.16 
(1.25-13.82) 
0.76 
(0.29-2.01) 
184/207 1.27 
(0.88-1.83) 
1.04 
(0.72-1.49) 
 
HDL cholesterol (mmol/l)      
1.0 or lower 7/23 Ref Ref 667/120 Ref Ref  
above 1.0 63/62 1.03 
(0.13-8.23) 
0.98 
(0.39-2.45) 
184/412 0.30 
(0.21-0.43) 
0.53 
(0.37-0.76) 
 
 Subgroup analysis by number of available 
measurements 
Subgroup analysis by Charlson comorbidity index 
 N of deaths 
(7 or 
less/more 
than 7) 
HR (95% CI) HR (95% CI) N of deaths 
(0/1-2/3 
points) 
HR (95% CI) HR (95% CI) HR (95% CI) 
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5 or lower 621/237 Ref Ref 44/343/471 Ref Ref Ref 
above 5 452/120 0.60 
(0.43-0.82) 
0.81 
(0.50-1.31) 
36/242/294 0.41 
(0.15-1.11) 
0.51 
(0.34-0.75) 
0.75 
(0.51-1.12) 
LDL 
cholesterol 
(mmol/l) 
       
3 or lower 515/270 Ref Ref 42/265/478 Ref Ref Ref 
above 3 239/75 0.41 
(0.28-0.62) 
0.80 
(0.49-1.31) 
15/119/180 0.11 
(0.01-0.83) 
0.56 
(0.36-0.88) 
0.60 
(0.38-0.94) 
Triglycerides 
(mmol/l) 
       
1.7 or lower 802/236 Ref Ref 60/460/227 Ref Ref Ref 
above 1.7 262/121 1.20 
(0.86-1.67) 
1.28 
(0.84-1.95) 
21/143/774 2.43 
(1.06-5.55) 
1.12 
(0.76-1.66) 
1.01 
(0.70-1.47) 
HDL 
cholesterol 
(mmol/l) 
       
1.0 or lower 200/71 Ref Ref 19/95/157 Ref Ref Ref 
above 1.0 589/280 0.42 
(0.30-0.59) 
0.44 
(0.30-0.67) 
41/307/521 0.14 
(0.05-0.37) 
0.26 
(0.18-0.37) 
0.67 
(0.46-0.96) 
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3.5: Competing risks analysis 
In the competing risks analysis (supplement table 3), serum total cholesterol and triglycerides were positively associated with cancer mortality 
(HR 1.17, CI95% 1.05-1.30 and HR 1.27, CI95% 1.14-1.43, respectively). In contrast, LDL and HDL cholesterol remained inversely associated with 
cancer mortality similar to the main analysis (HR 0.89, CI95% 0.78-1.02 and HR 0.64, CI95% 0.56-0.74, respectively).
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Supplement table 3: Competing risks analysis 
Lipid fraction Competing risks 
analysis 
 HR (95% CI) 
n of cancer 
deaths (non-
exposed/ 
exposed) 
858/572  
Total cholesterol   
5 or lower Ref 
above 5 
 
 
1.17 
(1.05-1.30) 
LDL     
3 or lower Ref 
above 3 0.89 
(0.78-1.02) 
HDL  
1 or lower Ref 
above 1 0.65 
(0.56-0.74) 
Triglycerides  
1.7 or lower Ref 
above 1.7 1.27 
(1.14-1.43) 
 
 
4: DISCUSSION 
As expected from the results of previous studies, an inverse association between serum total 
cholesterol and cancer mortality was observed. The association disappeared in long term analysis 
after 10 years’ time lag. However, our comprehensive data of the different lipid components in the 
long term reveals more about the exact nature of the relationship. 
 
The inverse association between serum cholesterol and all-cancer mortality persisted up to 10 
years in our lag time analysis. In analyses with longer time lag the risk estimates for 
hypercholesterolemia tended to increase, a trend which was observed separately for many 
individual cancer types. HDL cholesterol showed the strongest inverse association with cancer 
mortality. Both high HDL and LDL levels were associated with lowered cancer mortality. High 
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triglyceride levels were generally associated with increased, but not statistically significant risk 
estimates for cancer mortality. 
 
Previously it has been suggested that the apparent inverse association between serum total 
cholesterol levels and cancer is attributable to reverse causation due to the association 
disappearing when excluding the first years of follow-up7–11. The time-dependent analyses in our 
study produced similar results, supporting this hypothesis. 
 
A likely explanation for these findings is the increased lipid uptake by cancer cells. Increased de 
novo lipogenesis is a well-established trait of cancer metabolism3. More recently, however, its’ 
importance has been debated and there has been rising interest in the role of exogenous lipid 
uptake as well. Hypoxia, a common feature in solid tumors, has been shown to decrease enzyme 
activity in de novo lipogenesis pathways and simultaneously upregulate lipid uptake4,24,25. The 
phenomenon has been proposed to have a role in metastatic tumor progression26,27 and might 
even present a novel therapeutic target27,28. 
 
We also explored the effect of non-cancer mortality has on the association. In our competing risk 
analysis, where non-cancer mortality is accounted for, the inverse association turned into a risk 
increase, driven mainly by risk increase associated with high triglyceride level. For HDL and LDL, 
the risk decrease remained similar to the main analysis. This analysis, however, is not directly 
comparable with our main analysis because cholesterol levels could not be analyzed as a time-
dependent variable in the competing risks analysis. To produce a more comparable analysis we ran 
a non-time-dependent cox regression analysis (supplement table 4) that produced almost identical 
results with the competing risks analysis, indicating that the positive association is most likely a 
result of inability to account for changes in cholesterol levels over time. The effect modification by 
comorbidities was further explored in the subgroup analysis by Charlson comorbidity index points. 
The inverse association between HDL cholesterol and cancer mortality was strong among the low 
comorbidities group and weaker in the group with most comorbidities, demonstrating that 
competing causes of death tend to attenuate the risk association with cholesterol level rather than 
increase it. Therefore the risk decrease observed for high total cholesterol is unlikely to be 
explained by competing causes of death. 
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Supplement table 4: non-time-dependent cox regression analysis 
 
Lipid fraction Non-time 
dependent 
analysis 
 HR (95% CI) 
 
n of cancer 
deaths (non-
exposed/ 
exposed) 
858/572  
5 or lower Ref 
above 5 
 
 
1.17 
(1.05-1.30) 
LDL    
3 or lower Ref 
above 3 0.80 
(0.70-0.91) 
HDL  
1 or lower Ref 
above 1 0.54 
(0.47-0.62) 
Triglycerides  
1.7 or lower Ref 
above 1.7 1.44 
(1.29-1.62) 
 
 
We also studied the association between reduction in cholesterol levels among users of 
cholesterol-lowering statin drugs and cancer mortality to explore the possibility of serum 
cholesterol being a modifiable risk factor for cancer mortality. A reduction in cancer mortality has 
been previously observed among statin-users21, but the mechanism of action is still somewhat 
unclear. Both systemic reduction of circulating cholesterol levels as well as local tumor growth 
inhibitory effects on the cancer tissue have been proposed29. In our analysis, statin users whose 
serum total cholesterol decreased had a lower risk of cancer death compared to those whose 
cholesterol level did not change, but the risk difference was not statistically significant. Thus, our 
findings offer modest support for the hypothesis of systemic cholesterol level being a modifiable 
risk factor for cancer death, albeit our analysis might be lacking statistical power to properly 
explore the association. 
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A major strength of our study was the cohort being population-based, reducing the risk of 
selection bias. We also had data on all lipid fractions, which many of the previous studies lacked. 
The spontaneous decrease in serum cholesterol levels during cancer progression6 makes it 
important to analyze the association on a sufficiently long time span. We had access to several 
decades of lipid values allowed for analysis of measurements preceding cancer death for up to 20 
years. The lipid levels were treated as time-dependent variable in order to model for changes in 
cholesterol levels during the follow-up. Another strength was comprehensive drug prescription 
data acquired via national prescription database, making It possible to analyze cholesterol 
reduction during statin use. 
 
A limitation of our study was that cholesterol measurements were not obtained randomly; the 
factors leading to cholesterol measurement may introduce selection for certain types of 
individuals, for instance those with known cardiovascular risk factors or health-conscious people. 
Another weakness was lack of information on smoking status, exercise and diet, all of which are 
likely associated both with serum cholesterol levels and cancer mortality. 
 
A possible source of bias is that the number and frequency of cholesterol measurements was not 
standardized. Likely persons with hypercholesterolemia and/or cardiovascular disease were tested 
more often, making our data on cholesterol level more precise in this subgroup compared to men 
with no such problems and possibly only few measurements available as follow-up for cholesterol 
level was unnecessary. This selection was highlighted in population characteristics; proportion of 
statin users was higher in men whose mean cholesterol was below 5 mmol/l than in men with 
elevated cholesterol; such unexpected difference can be caused either by statin usage mainly for 
secondary prevention of cardiovascular disease irrespective of cholesterol level or because the 
mean cholesterol is mainly influenced by more numerous cholesterol measurements after statin 
use when the level has been normalized. When stratified by baseline cholesterol proportion of 
statin users was higher in the hypercholesterolemic group. However, the number of available 
measurements did not modify the risk association between cholesterol level and cancer mortality 
in subgroup analysis. Thus this bias is unlikely to affect our findings to any great degree. 
 
 
 
26 
 
5: Conclusion 
Hypercholesterolemia is associated with lowered cancer mortality for up to 10 years before cancer 
death, supporting reverse causation; i.e. spontaneously lowering cholesterol in people with fatal 
cancer. The risk association is unlikely to be explained by competing causes of death. Cholesterol-
lowering with statins may lower the risk of cancer death, supporting hypercholesterolemia as a 
modifiable cancer risk factor. 
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